-
1
-
-
0026091413
-
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
-
Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-1132.
-
(1991)
Arthritis Rheum
, vol.34
, pp. 1125-1132
-
-
Chu, C.Q.1
Field, M.2
Feldmann, M.3
-
2
-
-
0035932519
-
Cytokine pathways and joint inflammation in rheumatoid arthritis
-
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
-
(2001)
N Engl J Med
, vol.344
, pp. 907-916
-
-
Choy, E.H.1
Panayi, G.S.2
-
3
-
-
0142029950
-
Joint damage and disability in rheumatoid arthritis: An updated systematic review
-
Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003;21 (5 suppl 31):S20-S27.
-
(2003)
Clin Exp Rheumatol
, vol.21
, Issue.5 SUPPL. 31
-
-
Scott, D.L.1
Smith, C.2
Kingsley, G.3
-
4
-
-
0035555275
-
Pathogenesis of arthritis: Recent research progress
-
Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol 2001;2:771-773.
-
(2001)
Nat Immunol
, vol.2
, pp. 771-773
-
-
Feldmann, M.1
-
5
-
-
0036584028
-
Development of anti-TNF therapy for rheumatoid arthritis
-
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-371.
-
(2002)
Nat Rev Immunol
, vol.2
, pp. 364-371
-
-
Feldmann, M.1
-
6
-
-
0042925466
-
Infliximab treatment of rheumatoid arthritis and Crohn's disease
-
Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-1265.
-
(2003)
Ann Pharmacother
, vol.37
, pp. 1256-1265
-
-
Nahar, I.K.1
Shojania, K.2
Marra, C.A.3
-
7
-
-
60349128880
-
-
Humira (adalimumab) [package insert]. Abbott Park, IL Abbott Laboratories
-
Humira (adalimumab) Prescribing Information [package insert]. Abbott Park, IL, Abbott Laboratories, 2008.
-
(2008)
Prescribing Information
-
-
-
8
-
-
0034045894
-
Treatment options for rheumatoid arthritis: Celecoxib, leflunomide, etanercept, and infliximab
-
Luong BT, Chong BS, Lowder DM. Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. Ann Pharmacother 2000;34:743-760.
-
(2000)
Ann Pharmacother
, vol.34
, pp. 743-760
-
-
Luong, B.T.1
Chong, B.S.2
Lowder, D.M.3
-
10
-
-
43549105864
-
Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety
-
Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
-
(2008)
BMC Musculoskelet Disord
, vol.9
, pp. 52
-
-
Alonso-Ruiz, A.1
Pijoan, J.I.2
Ansuategui, E.3
-
11
-
-
44849131569
-
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
-
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893.
-
(2008)
Cochrane Database Syst Rev
, vol.1
-
-
Behm, B.W.1
Bickston, S.J.2
-
12
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT i randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359: 1541-1549.
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
-
13
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn's disease
-
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885.
-
(2004)
N Engl J Med
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
-
14
-
-
77958548914
-
-
Centocor. Available at: Accessed on May 17, 2008
-
Centocor. Remicade (infliximab) package insert. Available at: www. remicade.com/pdf/HCP-PPI.pdf. Accessed on May 17, 2008.
-
Remicade (Infliximab) Package Insert
-
-
-
15
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis
-
Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602.
-
(2000)
N Engl J Med
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
Van Der Heijde, D.M.2
St Clair, E.W.3
-
16
-
-
8444239359
-
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized controlled trial
-
Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group
-
St Clair EW, van der Heijde DMFM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3432-3443
-
-
St Clair, E.W.1
Van Der Heijde Dmfm2
Smolen, J.S.3
-
17
-
-
0038649858
-
The incidence and management of infusion reactions to infliximab: A large center experience
-
Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-1324.
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1315-1324
-
-
Cheifetz, A.1
Smedley, M.2
Martin, S.3
-
18
-
-
0033524159
-
Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
-
ATTRACT Study Group
-
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354: 1932-1939.
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
St Clair, E.W.2
Breedveld, F.3
-
19
-
-
0037434552
-
Influence of immunogenecity on the long-term efficacy of infliximab in Crohn's disease
-
Baert F, Noman M, Vermeire S, et al. Influence of immunogenecity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
-
20
-
-
0037379792
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
-
Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.
-
(2003)
Gastroenterology
, vol.124
, pp. 917-924
-
-
Farrell, R.J.1
Alsahli, M.2
Jeen, Y.T.3
-
22
-
-
0036106469
-
Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion
-
Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8:186-191.
-
(2002)
Inflamm Bowel Dis
, vol.8
, pp. 186-191
-
-
Riegert-Johnson, D.L.1
Godfrey, J.A.2
Myers, J.L.3
-
23
-
-
0036020424
-
Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: A case series
-
Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002;35:149-150.
-
(2002)
J Clin Gastroenterol
, vol.35
, pp. 149-150
-
-
Kane, S.1
Stone, L.J.2
Ehrenpreis, E.3
-
24
-
-
1242313906
-
Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients
-
Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004;63:156-161.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 156-161
-
-
Feletar, M.1
Brockbank, J.E.2
Schentag, C.T.3
-
25
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
-
26
-
-
38549118358
-
Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab
-
Fabre C, Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008;216:185-186.
-
(2008)
Dermatology
, vol.216
, pp. 185-186
-
-
Fabre, C.1
Dereure, O.2
-
27
-
-
4043107880
-
Alopecia areata in a patient using infliximab: New insights into the role of tumor necrosis factor on human hair follicles
-
Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004;140:1012.
-
(2004)
Arch Dermatol
, vol.140
, pp. 1012
-
-
Ettefagh, L.1
Nedorost, S.2
Mirmirani, P.3
-
28
-
-
34548715787
-
Two cases of atopic dermatitis- like conditions induced in psoriasis patients treated with infliximab
-
Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis- like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 2007;21:1272-1274.
-
(2007)
J Eur Acad Dermatol Venereol
, vol.21
, pp. 1272-1274
-
-
Vestergaard, C.1
Deleuran, M.2
Kragballe, K.3
-
29
-
-
33846203357
-
Infliximab-induced acne: Report of two cases
-
Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007;156:402-403.
-
(2007)
Br J Dermatol
, vol.156
, pp. 402-403
-
-
Bassi, E.1
Poli, F.2
Charachon, A.3
-
31
-
-
0037640033
-
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy
-
Devos SA, Van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206:388-390.
-
(2003)
Dermatology
, vol.206
, pp. 388-390
-
-
Devos, S.A.1
Van Den Bossche, N.2
De Vos, M.3
-
32
-
-
5044237150
-
Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents
-
Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-1958.
-
(2004)
J Rheumatol
, vol.31
, pp. 1955-1958
-
-
Mohan, N.1
Edwards, E.T.2
Cupps, T.R.3
-
33
-
-
67651182541
-
Tumor NECROSIS FACTOR ALPHA (TNF-a) ANTAGONISTSS [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: Serious skin reactions
-
United States Food and Drug Administration
-
United States Food and Drug Administration: Tumor NECROSIS FACTOR ALPHA (TNF-a) ANTAGONISTSS [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions. FDA Drug Safety News 2008;1:18-22.
-
(2008)
FDA Drug Safety News
, vol.1
, pp. 18-22
-
-
-
34
-
-
0036232867
-
Antitumour necrosis factoralpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis
-
Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factoralpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:707-709.
-
(2002)
Br J Dermatol
, vol.146
, pp. 707-709
-
-
Fischer, M.1
Fiedler, E.2
Marsch, W.C.3
-
35
-
-
25844469530
-
Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment
-
Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005;116:923-924.
-
(2005)
J Allergy Clin Immunol
, vol.116
, pp. 923-924
-
-
Hunger, R.E.1
Hunziker, T.2
Buettiker, U.3
-
37
-
-
0034953354
-
Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor alpha receptor: Fc fusion protein
-
Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001;137:893-899.
-
(2001)
Arch Dermatol
, vol.137
, pp. 893-899
-
-
Zeltser, R.1
Valle, L.2
Tanck, C.3
-
38
-
-
73849133005
-
-
ENBREL(R) Wyeth Europe Ltd
-
ENBREL(R) Subcutaneous Injection. Wyeth Europe Ltd; 2008.
-
(2008)
Subcutaneous Injection
-
-
-
39
-
-
10444264483
-
Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept
-
Rajakulendran S, Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology (Oxford) 2004;43:1588-1589.
-
(2004)
Rheumatology (Oxford)
, vol.43
, pp. 1588-1589
-
-
Rajakulendran, S.1
Deighton, C.2
-
40
-
-
35348996005
-
Recall injection-site reactions associated with etanercept therapy: Report of two new cases with immunohistochemical analysis
-
González-López MA, Martínez-Taboada VM, González-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32:672-674.
-
(2007)
Clin Exp Dermatol
, vol.32
, pp. 672-674
-
-
González-López, M.A.1
Martínez-Taboada, V.M.2
González-Vela, M.C.3
-
41
-
-
33646043438
-
Etanercept-induced dermatitis in a patient with rheumatoid arthritis
-
Lai-Cheong J, Warren R, Bucknall R, et al. Etanercept-induced dermatitis in a patient with rheumatoid arthritis. J Eur Acad Dermatol Venereol 2006;20:614-615.
-
(2006)
J Eur Acad Dermatol Venereol
, vol.20
, pp. 614-615
-
-
Lai-Cheong, J.1
Warren, R.2
Bucknall, R.3
-
43
-
-
63149107564
-
Urticaria due to etanercept in a patient with psoriatic arthiritis
-
Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Urticaria due to etanercept in a patient with psoriatic arthiritis. South Med J 2009; 102:304-305.
-
(2009)
South Med J
, vol.102
, pp. 304-305
-
-
Borrás-Blasco, J.1
Gracia-Perez, A.2
Rosique-Robles, J.D.3
-
45
-
-
0036720328
-
Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis
-
Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 2002;61:850-851.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 850-851
-
-
Soliotis, F.1
Glover, M.2
Jawad, A.S.3
-
47
-
-
34548160239
-
Acute generalized skin eruption due to adalimumab: Report of two cases
-
Dalmau J, Roé E, Corella F, et al. Acute generalized skin eruption due to adalimumab: report of two cases. J Eur Acad Dermatol Venereol 2007;21:1105-1106.
-
(2007)
J Eur Acad Dermatol Venereol
, vol.21
, pp. 1105-1106
-
-
Dalmau, J.1
Roé, E.2
Corella, F.3
-
48
-
-
33845684650
-
Development of alopecia areata universalis in a patient receiving adalimumab
-
Garcia Bartels N, Lee HH, Worm M, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006;142:1654-1655.
-
(2006)
Arch Dermatol
, vol.142
, pp. 1654-1655
-
-
Garcia Bartels, N.1
Lee, H.H.2
Worm, M.3
-
50
-
-
33750689883
-
Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab
-
Sànchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, et al. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol 2006;24(5 Suppl 42):S128.
-
(2006)
Clin Exp Rheumatol
, vol.24
, Issue.5 SUPPL. 42
-
-
Sànchez-Cano, D.1
Callejas-Rubio, J.L.2
Ortego-Centeno, N.3
-
52
-
-
34548461646
-
Adalimumab-induced urticaria
-
[in Spanish]
-
Mallo S, Santos-Juanes J. [Adalimumab-induced urticaria]. Actas Dermosifiliogr 2007;98:511-512 [in Spanish].
-
(2007)
Actas Dermosifiliogr
, vol.98
, pp. 511-512
-
-
Mallo, S.1
Santos-Juanes, J.2
-
53
-
-
34147150251
-
Urticaria and angiedema-like skin reactions in a patient treated with adalimumab
-
Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007; 26:787-788.
-
(2007)
Clin Rheumatol
, vol.26
, pp. 787-788
-
-
Nikas, S.N.1
Voulgari, P.V.2
Drosos, A.A.3
-
55
-
-
34447515607
-
Maintenance therapy with certolizumab pegol for Crohn's disease
-
DOI 10.1056/NEJMoa062897
-
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239-250. (Pubitemid 47080388)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.3
, pp. 239-250
-
-
Schreiber, S.1
Khaliq-Kareemi, M.2
Lawrance, I.C.3
Thomsen, O.O.4
Hanauer, S.B.5
McColm, J.6
Bloomfield, R.7
Sandborn, W.J.8
-
56
-
-
73849142076
-
-
CIMZIA(R) SC Injection, UCB Inc, Smyrna GA
-
CIMZIA(R) SC Injection, Certolizumab Pegol SC Injection. UCB Inc, Smyrna, GA, 2008.
-
(2008)
Certolizumab Pegol SC Injection
-
-
-
57
-
-
0033574147
-
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
-
Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486.
-
(1999)
Ann Intern Med
, vol.130
, pp. 478-486
-
-
Moreland, L.W.1
Schiff, M.H.2
Baumgartner, S.W.3
-
58
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
Keystone, E.C.2
Furst, D.E.3
-
59
-
-
24944532440
-
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study
-
Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-R676.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
Flendrie, M.1
Vissers, W.H.2
Creemers, M.C.3
-
60
-
-
33846950349
-
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factoralpha antagonists
-
Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factoralpha antagonists. Br J Dermatol 2007;156:486-491.
-
(2007)
Br J Dermatol
, vol.156
, pp. 486-491
-
-
Lee, H.H.1
Song, I.H.2
Friedrich, M.3
-
61
-
-
36749030680
-
Tumor necrosis factor as a therapeutic target of rheumatologic disease
-
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11: 1369-1384.
-
(2007)
Expert Opin Ther Targets
, vol.11
, pp. 1369-1384
-
-
Ackermann, C.1
Kavanaugh, A.2
-
62
-
-
34247218183
-
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
-
Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-1133.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1125-1133
-
-
Curtis, J.R.1
Patkar, N.2
Xie, A.3
-
63
-
-
23644447586
-
Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction
-
Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-2518.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2513-2518
-
-
Sfikakis, P.P.1
Iliopoulos, A.2
Elezoglou, A.3
-
64
-
-
10344256237
-
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors
-
Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-1495.
-
(2004)
Arch Dermatol
, vol.140
, pp. 1490-1495
-
-
Gilliet, M.1
Conrad, C.2
Geiges, M.3
-
65
-
-
33846974080
-
Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions
-
de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231.
-
(2007)
Arch Dermatol
, vol.143
, pp. 223-231
-
-
De Gannes, G.C.1
Ghoreishi, M.2
Pope, J.3
-
66
-
-
37549005087
-
Tumor necrosis factor-alpha inhibitor- induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients
-
Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor- induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
-
(2008)
Am J Clin Dermatol
, vol.9
, pp. 1-14
-
-
Wollina, U.1
Hansel, G.2
Koch, A.3
-
67
-
-
43049115714
-
Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab
-
Borrás-Blasco J, Gracia-Perez A, Nuñez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008;33:321-325.
-
(2008)
J Clin Pharm Ther
, vol.33
, pp. 321-325
-
-
Borrás-Blasco, J.1
Gracia-Perez, A.2
Nuñez-Cornejo, C.3
-
68
-
-
47249159958
-
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action
-
Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
-
(2008)
Arthritis Rheum
, vol.59
, pp. 996-1001
-
-
Collamer, A.N.1
Guerrero, K.T.2
Henning, J.S.3
-
69
-
-
21744446004
-
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey
-
De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-R551.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
De Bandt, M.1
Sibilia, J.2
Le Loët, X.3
-
70
-
-
0033763979
-
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
-
Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-2390.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 2383-2390
-
-
Charles, P.J.1
Smeenk, R.J.2
De Jong, J.3
-
71
-
-
33749318283
-
IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis
-
Visvanathan S, Wagner C, Smolen J, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:2840-2844.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2840-2844
-
-
Visvanathan, S.1
Wagner, C.2
Smolen, J.3
-
72
-
-
79955508939
-
Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays
-
Russell E, Zeihen M, Wergin S, et al. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum 2000;43:944.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 944
-
-
Russell, E.1
Zeihen, M.2
Wergin, S.3
-
73
-
-
0036208520
-
Dermatological complications of etanercept therapy for rheumatoid arthritis
-
Misery L, Perrot JL, Gentil-Perret A, et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002; 146:334-335.
-
(2002)
Br J Dermatol
, vol.146
, pp. 334-335
-
-
Misery, L.1
Perrot, J.L.2
Gentil-Perret, A.3
-
74
-
-
0037116836
-
Drug-induced systemic lupus erythematosus associated with etanercept therapy
-
DOI 10.1016/S0140-6736(02)07714-0
-
Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-580. (Pubitemid 34178442)
-
(2002)
Lancet
, vol.359
, Issue.9306
, pp. 579-580
-
-
Shakoor, N.1
Michalska, M.2
Harris, C.A.3
Block, J.A.4
-
75
-
-
36849005577
-
Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis
-
Bout-Tabaku S, Rivas-Chacon R, Restrepo R. Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis. J Rheumatol 2007;34:2503-2504.
-
(2007)
J Rheumatol
, vol.34
, pp. 2503-2504
-
-
Bout-Tabaku, S.1
Rivas-Chacon, R.2
Restrepo, R.3
-
76
-
-
44349171691
-
Drug-induced lupus due to anti-tumor necrosis factor alpha agents
-
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-387.
-
(2008)
Semin Arthritis Rheum
, vol.37
, pp. 381-387
-
-
Costa, M.F.1
Said, N.R.2
Zimmermann, B.3
-
77
-
-
35448960902
-
Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNFalpha therapy for psoriatic arthritis
-
[in German]
-
Haake H, Köneke J, Amann K, et al. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNFalpha therapy for psoriatic arthritis]. Med Klin (Munich) 2007;102:852-857 [in German].
-
(2007)
Med Klin (Munich)
, vol.102
, pp. 852-857
-
-
Haake, H.1
Köneke, J.2
Amann, K.3
-
78
-
-
33750243673
-
Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis
-
Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006; 21:946-949.
-
(2006)
J Korean Med Sci
, vol.21
, pp. 946-949
-
-
Kang, M.J.1
Lee, Y.H.2
Lee, J.3
-
79
-
-
18644374205
-
Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease
-
Richez C, Blanco P, Dumoulin C, et al. Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease. Clin Exp Rheumatol 2005;23:273.
-
(2005)
Clin Exp Rheumatol
, vol.23
, pp. 273
-
-
Richez, C.1
Blanco, P.2
Dumoulin, C.3
-
80
-
-
11144355274
-
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
-
van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-516.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 508-516
-
-
Van De Putte, L.B.A.1
Atkins, C.2
Malaise, M.3
-
81
-
-
33749645144
-
Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level
-
van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford) 2006;45:1317-1319.
-
(2006)
Rheumatology (Oxford)
, vol.45
, pp. 1317-1319
-
-
Van Rijthoven, A.W.1
Bijlsma, J.W.2
Canninga-Van Dijk, M.3
-
82
-
-
34047260574
-
Drug-induced lupus erythematosus in a patient treated with adalimumab
-
Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol 2007;56(5 suppl): S114-S116.
-
(2007)
J Am Acad Dermatol
, vol.56
, Issue.5 SUPPL.
-
-
Spillane, A.P.1
Xia, Y.2
Sniezek, P.J.3
-
84
-
-
41149084506
-
Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab
-
Mañosa M, Domènech E, Marín L, et al. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab. Gut 2008;57:559.
-
(2008)
Gut
, vol.57
, pp. 559
-
-
Mañosa, M.1
Domènech, E.2
Marín, L.3
-
85
-
-
48249153854
-
Adalimumab-induced lupus erythematosus
-
Martín JM, Ricart JM, Alcácer J, et al. Adalimumab-induced lupus erythematosus. Lupus 2008;17:676-678.
-
(2008)
Lupus
, vol.17
, pp. 676-678
-
-
Martín, J.M.1
Ricart, J.M.2
Alcácer, J.3
-
86
-
-
55249092320
-
Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab
-
Havel J, Aboutalebi S, Doughty L, et al. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab. J Drugs Dermatol 2008;7: 796-798.
-
(2008)
J Drugs Dermatol
, vol.7
, pp. 796-798
-
-
Havel, J.1
Aboutalebi, S.2
Doughty, L.3
-
87
-
-
39049194497
-
Drug-induced lupus: An update
-
Vasoo S. Drug-induced lupus: an update. Lupus 2006;15:757-761.
-
(2006)
Lupus
, vol.15
, pp. 757-761
-
-
Vasoo, S.1
-
88
-
-
0036839482
-
New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis (letter)
-
Cairns AP, Duncan MK, Hinder AE, et al. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis (letter). Ann Rheum Dis 2002;61:1031-1032.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 1031-1032
-
-
Cairns, A.P.1
Duncan, M.K.2
Hinder, A.E.3
-
89
-
-
0036439854
-
Drug-induced lupus following treatment with infliximab in rheumatoid arthritis
-
Favalli EG, Sinigaglia L, Varenna M, et al. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11: 753-755.
-
(2002)
Lupus
, vol.11
, pp. 753-755
-
-
Favalli, E.G.1
Sinigaglia, L.2
Varenna, M.3
-
90
-
-
34250343172
-
Lessons for lupus from tumor necrosis factor blockade
-
De Bandt M. Lessons for lupus from tumor necrosis factor blockade. Lupus 2006;15:762-767.
-
(2006)
Lupus
, vol.15
, pp. 762-767
-
-
De Bandt, M.1
-
91
-
-
0036207308
-
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: Direct and indirect evidence for a possible association with infections
-
Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-361.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 358-361
-
-
Ferraccioli, G.1
Mecchia, F.2
Di Poi, E.3
|